42 results about "St elevation myocardial infarction" patented technology

Preferred systems for assisting clearance of an acutely thrombosed artery substantially surrounded by boney external body surfaces which are resistant to deformative displacement relative to the thrombosed artery by the application of external percussive force are described. The method consists of applying targeted, localized, non-invasive, high infrasonic to low sonic frequency vibratory percussion with a serial impact frequency much greater than the pulse rate of a patient being treated, the percussion directed towards a remote, preferably superficial “target vessel” residing palpably close to the skin surface. Marked vessel deformations with resultant blood pressure and flow fluctuations are thereby induced by the percussion within the target vessel which propagate to the acutely thrombosed artery to provide localized agitation and turbulence to assist thrombolytic and / or IV microbubble delivery and effectiveness in facilitating reperfusion. Preferred apparatus for treatment of ST elevation myocardial infarction, acute ischemic stroke and acute pulmonary embolus are presented.

Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction.

The related three-in-one detection agent plate for early diagnosis for AMI comprises: using GPBB, h-FABP and TpP as diagnosis index, fixing colloid gold amrked three antibodies and solid unmarked antibody for one-time detection. This invention is simple, has high sensitivity ans strong specificity, and fit to most place.

The invention relates to an acute myocardial infarction marker and an application thereof, and in particular relates to RFX2 and an application of an agonist thereof in preparing a medicine for diagnosis and treatment on acute myocardial infarction. Based on a high-flux sequencing result, the inventor screens out the RFX2 gene; a molecular biology method verifies that RFX2 has low expression in the peripheral blood and the cardiac muscle tissue of the acute myocardial infarction. The invention provides the potential diagnosis and treatment target spot of the acute myocardial infarction, and has great clinical application values.

The invention relates to the field of medical diagnosis and in particular to a kit for predicting the risk of acute myocardial infarction. The kit comprises detection reagents of microRNA-22-5p and / ormicroRNA-375. The invention further relates to application of microRNA-22-5p and / or microRNA-375 as molecular markers in preparing diagnosis agents for predicting the risk of acute myocardial infarction. The kit provided by the invention has very good diagnosis and prediction effects on AMI (Acute Myocardial Infarction) and is capable of predicting the disease risk of AMI, instructing preventionand treatment on AMI and alleviating threats of AMI.

The present invention relates to systems and methods for preparing and completing surgical and medical procedures. In particular, the invention relates to kits for improving preparation and completion time for a medical or surgical procedure in which the kit includes modularized compartments containing sterilized medical or surgical equipment and wherein the medical or surgical equipment is organized and / or ordered within the kit to generally correspond to the sequence of steps of the medical or surgical procedure. The kit is particularly applicable to recanalization procedures for stroke patients as well as revascularization procedures for acute myocardial infarction patients where a kit enables faster preparation and completion of these procedures.

The invention relates to the technical field of genetic engineering, and discloses long-chain non-encoded RNA ENST00000581794.1 as well as a kit and an application thereof. The sequence of the long-chain non-encoded RNA ENST00000581794.1 is as shown in SEQ ID NO:1. A long-chain non-encoded expression profile chip technique is used, and a piece of lncRNA ENST00000581794.1 which is remarkably and highly expressed in blood of patients suffering from acute myocardial infarction can be screened through differential analysis, so that study on pathogenesis of acute myocardial infarction is further enriched.

The invention provides a twelve-lead standard electrocardiogram acute myocardial infarction intelligent determining system based on artificial intelligence. The twelve-lead standard electrocardiogramacute myocardial infarction intelligent determining system comprises a data acquisition system and a cloud platform data storage system. The data acquisition system is in communication connection withthe cloud platform data storage system. The cloud platform data storage system is connected with a data modeling analysis system. The data modeling analysis system is connected with a data display system. The data acquisition system comprises an electrocardiogram acquisition system, an angiography device, a clinical testing observing table, and time between chest ache occurring and electrocardiogram acquiring. The twelve-lead standard electrocardiogram acute myocardial infarction intelligent determining system depends on a big data cloud platform and establishes an artificial intelligence algorithm based on characteristic identification acute myocardial infarction (fixed property, fixed position and fixed time) of the twelve-lead standard electrocardiogram, thereby establishing a whole myocardial infarction automatic determining intelligent system platform, quickly realizing acute myocardial infarction automatic determining, and improving diagnosis efficiency.

The invention provides an application of an miRNA marker for diagnosing acute myocardial infarction, a product using the miRNA marker and a detection method, and relates to the technical field of medical molecular biology. The miR-26a-1, miR-146a or miR-199a-1 can be singly or jointly applied as markers for assisting early diagnosis of myocardial infarction, and the plasma level of the miR-26a-1,miR-146a or miR-199a-1 is obviously increased in the early stage of occurrence of myocardial infarction; and the miRNA in the blood of patients with acute myocardial infarction is released into the blood earlier than intracellular protein markers, so that the detection of the plasma level of the miRNA can be used as a biomarker for assisting early diagnosis of acute myocardial infarction. The three miRNA markers can be used as markers for early diagnosis of heart diseases, and thus the sensitivity and specificity of disease diagnosis are greatly improved.

The invention relates to the technical field of gene engineering, and relates to a long non-coding RNA ENST00000509938.1, and a kit and an application thereof. The long non-coding RNA and a preparation or a diagnostic agent or a drug or the kit and the application thereof are provided; a gene sequence of the long non-coding RNA has a sequence as shown in SEQ ID No:1. Compared with the blood content of health people, the long non-coding RNA ENST00000509938.1 is significantly highly expressed in blood of patients with acute myocardial infarction. The long non-coding RNA ENST00000509938.1 can further enrich researches on a pathogenesis of acute myocardial infarction, and also provides new blood biomarkers and therapeutic targets for early diagnosis and prognosis monitoring of acute myocardial infarction.

The invention discloses application of EMD638683 in protection of the heart suffering from acute myocardial infarction. The invention provides application of EMD638683 in preparation of products having the following functions: 1) prevention and / or treatment of myocardial infarction of animals; 2) prevention and / or treatment of heart failure caused by myocardial infarction of animals; and 3) inhibition of the expression of SGK1 protein in cardiac muscle tissue after myocardial infarction of animals. Experimental results of the invention prove that EMD638683 has treatment effect on mice with myocardial infarction, and experimental data is provided for clinical application of EMD638683 in treatment of myocardial infarction. The EMD638683 is of important theoretical significance to research on and development of medicines used for preventing and treating heart failure caused by myocardial infarction and has good application prospects.

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)) are provided.

The invention discloses a recombinant protein AGGF1. The recombinant protein AGGF1 can improve the cardiac function of a mouse with acute myocardial infarction and inhibit myocardial apoptosis and cardiac fibrosis by promoting angiogenesis in the heart of the mouse. Thus, the recombinant protein AGGF1 can be used for preparation of angiogenesis promoting drugs for treatment of ischemic diseases. Meanwhile, the recombinant protein AGGF1 can improve the cardiac function of the mouse and inhibit cardiac fibrosis by inhibiting vascular leakage and oedema in cardiac muscles after the operation of cardiac ischemia reperfusion. Thus, the recombinant protein AGGF1 provided by the invention can be used for preparation of drugs for inhibiting vascular leakage to treat vascular leakage, oedema and dysfunction caused by cardiac ischemia reperfusion.

Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction.

The invention belongs to the field of small nucleic acid medicament pharmacy, and relates to an application of a miR-30 family inhibitor in preparation of a medicament for preventing and treating acute myocardial infarction. The results of experimental studies using an in vitro ischemic and anoxic cell model and an in vivo myocardial infarction model show that the miR-30 family inhibitor increases the generation of H2S by increasing expression of cystathionine-gamma-lyase (CSE), thereby protecting in vitro cell damages caused by ischemia and hypoxia, protecting mouse acute myocardial infarction damages caused by ligation of coronary arteries, and determining that the miR-30 family inhibitor has an obvious protective action on myocardial damages caused by ischemia and hypoxia. The miR-30 family inhibitor can be used as a new medicament for protecting damages of acute myocardial infarction.

A method and system for treating a patient having an acute myocardial infarction. Such system may comprise at least one tank having a pressurized gas contained therein, at least one housing having a shell and being adapted to at least partially surround a body segment of the patient, a hose / valve device for supplying the compressed gas from the tank to the housing; and a control device for controlling the flow of compressed gas from the tank to the housing in accordance with cardiac systole and cardiac diastolic of the patient to vary the pressure in synchronization with the patient's heart function. The system may be arranged within a moving vehicle, such as an ambulance, an airplane, or a ship.

The present application refers to the use of cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, for the treatment of acute myocardial infarction (AMI or Ml), wherein the cells, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, are encapsulated in a (spherical) microcapsule to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or of a pharmaceutical composition containing these cells or (spherical) microcapsule(s) for the treatment of acute myocardial infarction (AMI or Ml).

The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and / or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage of LRP1 by means of certain agents, including a recombinant expression vector, an RNAi, an antibody, a siRNA etc., prevents the overaccumulation of esterified cholesterol in the cardiomyocytes and / or in the smooth muscle cells of the vascular wall exposed to ischaemia. The invention also relates to the use of said molecules in the treatment and / or prevention of the changes in the metabolism of calcium and cardiac remodeling associated with ischaemia.

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.

The invention discloses a gene for screening acute myocardial infarction complicated by cardiac rupture and an expression product thereof, which are characterized by application of the platelet factor4(PF4) gene and the expression product thereof to the preparation of an acute myocardial infarction risk prediction marker and a diagnostic preparation. The acute myocardial infarction risk prediction marker and the diagnostic preparation adopt conventional PCR (Polymerase Chain Reaction) relative quantification, a fluorescent quantification kit, protein hybridization, an enzyme-linked immunoassay method and a gene chip to assay the expression level of gene in the peripheral blood of a subject or a patient with acute myocardial infarction. The invention provides the application of the PF4 gene and / or the expression product of the gene as a novel marker for screening acute myocardial infarction complicated by cardiac rupture, provides a novel method for predicting and diagnosing the risk of acute myocardial infarction complicated by cardiac rupture by means of the PF4 gene or the expression product of the gene and utilizes the PF4 gene and the expression product thereof to prepare themarker for predicting the risk of acute myocardial infarction complicated by cardiac rupture and the diagnostic preparation for the first time.

The present invention relates to an improved method for accelerating restoration of blood flow in treatment of an acutely thrombosed coronary artery by employing real time transthoracic 3D ultrasonic volume imaging at or near the base of the heart, and / or proximate the basal aspect of the associated left ventricular regional wall motion abnormality. Ultrasonic pulses provided by 3D imaging uniquely and necessarily deliver ultrasound to a broad target volume to stimulate the coronary arteries (which are difficult to image with ultrasound, and comprise tortious three dimensional structures), in view to providing an agitative and clot disruptive effect to a hidden, culprit, thrombosed, coronary vessel. In the preferred embodiment an intravenous microbubble solution is concurrently administered with 3D ultrasound which creates a dramatic synergy in disrupting the culprit thrombosis. Further incorporation of intravenously administered thrombolytics and co-use of transthoracic low frequency sonic vibration massage along with 3D ultrasonic imaging and microbubbles (including whereby thrombolytics are contained within microbubbles) to expedite initial reflow and facilitate microvascular flow (in avoidance of the no-reflow phenomenon following epicardial vessel recanalization) are also discussed.

The invention discloses joint application of dihydrotanshinone I and protocatechualdehyde to preparation of medicines for treating acute myocardial infarction and particularly provides a medicine for treating acute myocardial infarction. Active components of the medicine include dihydrotanshinone I and protocatechualdehyde. A pharmaceutical preparation for treating acute myocardial infarction comprises the active components and a pharmaceutically acceptable carrier or excipient and is made into a pharmaceutically acceptable form. The joint application has advantages that toxicity of dihydrotanshinone I is reduced while efficacy advantages of the dihydrotanshinone I are achieved, namely myocardial infarction area of acute myocardial infarction rats can be effectively reduced, long drug action is realized, and toxic lethality is evidently decreased. Further, treatment effects of the dihydrotanshinone I on the myocardial infarction rats can be evidently improved by addition of protocatechualdehyde in different doses, and the dihydrotanshinone I and the protocatechualdehyde have an efficacy synergistic effect.

This invention relates to TAFI inhibitors and their use to enhance myocardial reperfusion and facilitate percutaneous coronary intervention (PCI) in the treatment of acute ST elevation myocardial infarction (STEMI).

Compositions, kits and methods are provided for preventing or treating tissue injury caused by stresses or shocks related to oxygen deficiency, such as ischemia, anoxia, hypoxia, reperfusion and other environmental stresses. In particular, protein kinase C (PKC) isozyme-specific agonists and antagonists are provided for treating cardiac tissue damage due to ischemia-reperfusion, such as acute myocardial infarction.

The invention relates to application of small-molecule miRNA146a-5p, miRNA3135b and miRNA26b-5p to preparation of medicines for assessing acute myocardial infarction, application to preparation of medicines for diagnosing acute myocardial infarction, and a kit used for the application. According to the application disclosed by the invention, stable miRNA in exosome is detected, while a molecular marker detected by the traditional method is a protein polypeptide. In quantitative determination, the miRNA has extremely high quantitative precision and sensitivity, and single molecule detection ability can be reached by using an RT-qPCR technology. The application disclosed by the invention has the advantages of being convenient in material selection, simple in operation, high in specificity, rapid and accurate and provides a convenient and rapid screening technology for patients suffering from acute myocardial infarction.

The invention discloses a coronary artery thrombolytic agent for acute myocardial infarction. The coronary artery thrombolytic agent is prepared from, by weight, 0.5-2 parts of tirofiban, 5-10 parts of bivalirudin, 3-5 parts of tenecteplase, 0.4 part of sodium nitroprusside, 0.0032 part of unfractionated heparin and the balance normal saline, and the normal saline is used for diluting the mixture to obtain the volume which is 10 times of the original volume. Researches show that great advantages are brought when antiplatelet and anticoagulant drugs are administrated in a coronary artery based on PCI treatment, local drug concentration is high according to drug administration in the coronary, the needed thrombolytic drug dosage is small, thrombolysis is fast, the success rate is high, and few of hemorrhagic complications are caused. The coronary artery thrombolytic agent is used in cooperation with the intranperative radiography or intracavity radiological technology, thrombus changes can be dynamically monitored in real time, the best microthrombus dissolving effect is achieved, the PCI intraoperative no-reflow occurrence rate is lowered, and the prognosis of a patient is significantly improved.

The invention discloses a DSG3 gene as a molecular marker for early diagnosis of acute myocardial infarction. By utilization of a gene chip and a QPCR method, the situation is discovered that expressions of the DSG3 gene in blood of normal persons and patients with acute myocardial infarction show significant difference, and whether a subject suffers from acute myocardial infarction can be determined through detection of the expression situation of the DSG3 gene in blood. A kit for diagnosis of acute myocardial infarction is developed according to correlation. Diagnosis of acute myocardial infarction is carried out through detection of expression of the DSG3 by utilization of the kit. The diagnostic kit can be used for early diagnosis of diseases, and has wide application prospects in clinic.

The invention belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition for treating phlegm-turbidity blocking type STEMI (St-elevation myocardial infarction) direct PCI (percutaneous coronary interention) postoperative myocardial perfusion deficiency. The traditional Chinese medicine composition is prepared from the following ingredients in parts by weight: 2 to 4 parts of semen brassicae, 4 to 8 parts of acorus gramineus soland, 4 to 8 parts of Chinese alyxia herb, 4 to 8 parts of Bagusheng, 4 to 8 parts of dysosma versipellis, 4 to 8 parts of paeonia lactiflora, 4 to 8 parts of buddleja asiatica, 4 to 8 parts of plumbago indica and 4 to 8 parts of liquorice. All medicine is used and matched together for achieving the effects of eliminating phlegm for resuscitation, activating blood and dredging collaterals. The myocardial perfusion of a patient with STEMI direct PCI postoperative myocardial perfusion deficiency can be obviously improved.

The invention relates to a method of treating a subject who has suffered a myocardial infarction with ST-elevation and to a method of treating reperfusion injury in a subject, the method comprising intravenous administration of melatonin to the subject, wherein the administration is initiated within 3 hours or less of symptom onset and prior to the mechanical reperfusion and is maintained for at least 60 minutes.

A method for identifying an increased risk of developing ST-Segment Elevation Myocardial Infarction (STEMI) in a subject involves obtaining a platelet-containing plasma sample from the subject; determining a Prostaglandin E2 (PGE2) phenotype of the platelets of the subject; and identifying the subject has having an increased risk of developing STEMI when the subject has a potentiating phenotype, as compared to the risk of a subject having an inhibitory phenotype.